Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr2.52 DKK
Change Today -0.06 / -2.33%
Volume 62.9K
As of 6:04 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

bioporto a/s (BIOPOR) Snapshot

Open
kr2.58
Previous Close
kr2.58
Day High
kr2.58
Day Low
kr2.51
52 Week High
05/28/15 - kr3.24
52 Week Low
10/16/14 - kr1.35
Market Cap
297.0M
Average Volume 10 Days
253.3K
EPS TTM
kr-0.11
Shares Outstanding
117.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOPORTO A/S (BIOPOR)

Related News

No related news articles were found.

bioporto a/s (BIOPOR) Related Businessweek News

No Related Businessweek News Found

bioporto a/s (BIOPOR) Details

BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies for healthcare professionals in clinical and research settings in Denmark and internationally. The company offers the neutrophil gelatinase-associated lipocalin (NGAL) test, a particle-enhanced turbidimetric immunoassay for the determination of NGAL in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers; NGAL enzyme-linked immunosorbent assay (ELISA) kits for various animal models used for drug discovery purposes, as well as for human use; and mannose-binding lectin (MBL) ELISA kit, which is based on MBL antibodies to measure MBL levels. It also provides monoclonal antibodies under the AntibodyShop name that cover various research areas, such as microbiology, biomarkers, peptide hormones, and plasma proteins. In addition, the company offers matched antibody pairs, which include capture and detection antibodies that allow users to create their customized immunoassay solutions; matched reagent sets; human monoclonal IgE antigens for use in the field of allergy research and diagnostic kit manufacturing; and controls and calibrators, as well as human serum. BioPorto A/S was founded in 2000 and is based in Hellerup, Denmark.

26 Employees
Last Reported Date: 05/5/15
Founded in 2000

bioporto a/s (BIOPOR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bioporto a/s (BIOPOR) Key Developments

BioPorto Announces Progress in Clinical Trials for the FDA Application for the NGAL l Test™ and Launch of New Generic Strip Test

BioPorto has conducted a preliminary internal assessment of the data from the completed clinical trials in the USA. These data form the basis of the registration application to the FDA for approval of The NGAL Test™. The preliminary internal assessment of data support the further application process, including the formulation of the application, which is expected to be submitted to the FDA in September 2015 at the latest. The antibody portfolio is extended with a generic strip test under the name gRAD (Generic Rapid Assay Device). gRAD is a patented lateral flow test system that allows the R&D segment to develop and apply qualitative and quantitative rapid tests for the detection of, among other, viruses and bacteria in research and veterinary use. BioPorto has in licensed the test as it is a good match for the portfolio of antibodies. The launch of the test does not affect the outlook for 2015, but is expected to become a significant product in the AntibodyShop portfolio over time.

BioPorto A/S Reports Earnings Results for the First Quarter of 2015; Maintains Earnings Guidance for the Full Year of 2015

BioPorto A/S reported earnings results for the first quarter of 2015. BioPorto generated revenue of DKK 4.1 million in first quarter 2015, against DKK 4.8 million in the year-earlier period, when revenue was positively affected by license income from Abbott. Net of this income, revenue was up by approximately 14% compared with first quarter 2014. EBIT was a loss of DKK 4.4 million against a loss of DKK 3.6 million in 2014, and the loss for the period was DKK 4.0 million against a loss of DKK 3.6 million in 2014. Loss before tax was DKK 4.487 million against DKK 3.612 million a year ago. Cash flow from operations was DKK 3.410 million against DKK 5.414 million a year ago. Negative return on equity was 15% against 9% a year ago. Loss per share (lps/dps) was DKK 0.03 against DKK 0.03 loss per share a year ago. Purchase of tangible assets was DKK 0.033 million against DKK 0.361 million a year ago. The company maintained earnings guidance for the full year of 2015. Revenue is expected to be DKK 22 million to DKK 25 million in 2015, representing an increase of approximately 15%-35% on 2014. EBIT for 2015 is forecast at a loss between DKK 10 million and DKK 12 million, and it expects a net loss at the level of DKK 8 million to DKK 10 million, which would be a notable improvement on 2014.

BioPorto A/S, Q1 2015 Earnings Call, May 05, 2015

BioPorto A/S, Q1 2015 Earnings Call, May 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOPOR:DC kr2.52 DKK -0.06

BIOPOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr331.00 DKK +2.00
Chimerix Inc $53.71 USD +2.26
Emergent BioSolutions Inc $33.60 USD +0.81
PharmAthene Inc $1.73 USD +0.06
View Industry Companies
 

Industry Analysis

BIOPOR

Industry Average

Valuation BIOPOR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.3x
Price/Book 12.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOPORTO A/S, please visit www.bioporto.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.